Although previous clinical trials have shown that necitumumab, an anti-EGFR antibody combined with abemaciclib (a CDK4/6 inhibitor), did not produce an additive effect over single-agent activity in patients with stage IV NSCLC, no clinical studies have been conducted to explore the effectiveness of immunotherapy combined with a CDK4/6 inhibitor (22). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.